Protalix scores $25M milestone from Pfizer

The FDA's recent decision to approve the new Gaucher disease drug Elelyso (taliglucerase alfa) has triggered a $25 million payday for the Israeli biotech Protalix BioTherapeutics ($PLX). Pfizer ($PFE) partnered on the plant-derived enzyme treatment for the rare disease back in late 2009. Pfizer followed GlaxoSmithKline ($GSK) and other pharma companies that journeyed into the rare disease arena, paying $60 million upfront to partner with Protalix and agreeing to pay out up to $55 million in milestones. Pfizer holds the commercial rights to the drug outside of Israel. Story

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.